The Global Fabry Disease Market is expected to grow at a
CAGR of 6.8% during the forecast period. Technological advancements, strong
pipeline, advancements in healthcare facilities, and favorable funding policies
are expected to drive the market growth over the forecast period. Owing to the
increasing awareness about Fabry disease, new and existing market players are
coming up with better treatment approaches. For instance, in 2018, 2018, Amicus
Therapeutics launched Galafold capsules 123mg for the treatment of patients
aged 16 years and older with a confirmed diagnosis of Fabry disease and who
have an amenable mutation.
However, diverse range of symptoms, and related
complications can restrain the market growth over the assessment period.
Request Premium
Sample Report at https://www.marketresearchfuture.com/sample_request/7064
Key Players:
Some of the prominent players in the global Fabry disease
market are Amgen Inc., Amicus Therapeutics, Inc., AVROBIO, Inc., Idorsia
Pharmaceuticals Ltd, Protalix, Bristol-Myers Squibb Company, GlaxoSmithKline,
iBio, Inc., Neuraltus Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Sanofi,
Shire, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries
Ltd and others.
Segmentation:
The Global Fabry Disease Market has been segmented into
type, diagnosis & treatment and end user.
The market, on the basis of type, has been segmented into
type-1 and type-2. The type-2 Fabry disease holds the major market share due to
the high occurrence of type-2 Fabry disease i.e. 1 in 1,500 to 4000 males.
The market, by diagnosis & treatment, has been segmented
into diagnosis and treatment. The diagnosis segment is further classified as
blood test, urine test, thyroid test, lung function test, and imaging. The
imaging segment includes electrocardiogram (EKG), echocardiogram, brain MRI, CT
scan and others. The treatment segment is further classified as enzyme
replacement therapy, gene therapy, pharmaceutical formulations containing
agalsidase alfa, analgesics, anticonvulsants, nonsteroidal anti-inflammatory
drugs (NSAIDs), and others.
The market, by end user, has been segmented into hospitals
& clinics, diagnostic centers, research & academic institutes, and
others.
Regional Analysis:
Geographically, the Americas is expected to dominate the
global market owing to the increasing technological advancements and rising
research and development activities. Gastrointestinal manifestations such as
abdominal pain, diarrhea and nausea are significant burden in a patient with
Fabry disease. So, for the advanced treatment of these patients SmartPill
testing procedure is developed to gain additional understanding of Fabry
disease manifestation via motility abnormalities in order to improve symptom targeted
therapy. This device is currently under clinical trial and the sponsor of this
study is Massachusetts General Hospital.
Browse Complete 50
Pages Premium Research Report Enabled with Respective Tables And Figures At https://www.marketresearchfuture.com/reports/fabry-disease-market-7064
Europe is expected to hold the second largest market share.
Nearly 2.2 in 10,000 people in the European Union (EU) are affected with Fabry
disease and Fabrazyme (agalsidase beta), Galafold (migalastat) and Replagal
(agalsidase alfa) are the three authorized drugs used for the treatment of
Fabry disease.
Asia-Pacific is expected to be the fastest growing market
owing to the improving healthcare infrastructure.
Moreover, the Middle East and Africa region is expected to
hold the least market share in the global Fabry disease market.
About US:
Market Research Future (MRFR), enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845
9312
No comments:
Post a Comment